Research
Role of Pharmacists in Outcomes Research 02/21/2018 Reapproved | AMCP supports the role of pharmacists in outcomes research, including those processes by which health care systems identify treatment and/or procedural issues, complete interventions to correct deficiencies, and conduct evaluations to measure results and improve care in defined patient populations. In order to improve the appropriate use of medications, enhance favorable patient outcomes, and improve the cost-effectiveness and cost-efficiency of health care, managed health care systems must implement strategies based on credible, relevant outcomes research. Pharmacists are well positioned to design and implement programs and policies to influence the practice of prescribers and pharmacists and to evaluate the effect of these programs on patient outcomes.
|
Pharmacogenomics 02/21/2018 Reapproved | AMCP supports further research and assessment of the economic, clinical, and humanistic impact of pharmacogenomics on managed care pharmacy practice. AMCP supports the pharmacist's leadership role in the review and evaluation of scientific evidence and the subsequent development of pharmaceutical care processes involving these therapies through collaboration with other health care practitioners and consumer organizations. Pharmacy and Therapeutics Committees in collaboration with Health Technology Assessment committees should be involved in the decision-making process related to coverage of genetic tests and utilization management strategies. |
| Biosimilar Drug Therapies Policy 0802 06/01/2008 Introduced 04/01/2012 Revised 10/01/2012 Reapproved | AMCP supports an abbreviated licensure pathway for the approval of biosimilar biologic drug therapies. In order to strike an appropriate balance between bringing safe and effective drugs to market and maximizing patient access to affordable drugs, the FDA should determine on a case-by-case basis the need for additional clinical studies prior to approval, as well as any post-marketing studies. Manufacturers of approved biosimilars should be allowed to use the same government-approved/international non-proprietary name as the reference product. The FDA should also provide clear rules for the designation of a biosimilar product as interchangeable with a reference product, similar to the current “AB” ratings used for small-molecule chemical drugs. A designation of interchangeability should not be a requirement as a condition for approval of a biosimilar product.
|
Featured News & Resources
See Full CalendarUpcoming Events
AMCP offers a wide variety of educational opportunities, from events and webinars to online training.
